Evidence map›Paper›PMID 42013410›Full record

ArticleCancer discovery2026

AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors.

Jimin Min, Lisa Schweizer, Gijs Zonderland, Benson Chellakkan Selvanesan, Julie H Thomsen, Lukas Oldenburg, Seong-Woo Bae, Bongjun Kim, Sharía D Hernández, Gabriela Jez and 11 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Jimin Min *Laura and Isaac Perlmutter Cancer Center, Department of Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0002-2309-7875
Lisa Schweizer *Resolute Bio, Copenhagen, Denmark.ORCID 0000-0002-1165-7804
Gijs ZonderlandResolute Bio, Copenhagen, Denmark.ORCID 0000-0002-4820-6273
Benson Chellakkan SelvanesanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8013-1294
Julie H ThomsenResolute Bio, Copenhagen, Denmark.ORCID 0000-0002-0091-3614
Lukas OldenburgResolute Bio, Copenhagen, Denmark.ORCID 0009-0008-2395-1091
Seong-Woo BaeDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York.ORCID 0000-0001-6530-3983
Bongjun KimLaura and Isaac Perlmutter Cancer Center, Department of Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0001-7198-0411
Sharía D HernándezResolute Bio, Copenhagen, Denmark.ORCID 0000-0002-7746-0860
Gabriela JezResolute Bio, Copenhagen, Denmark.ORCID 0000-0001-6003-6708
Vincent BernardDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1555-608X
Benjamin J SwansonDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0006-1003-2630
Kelsey A KluteDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-4748-8520
Huamin WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2038-5863
Thomas C CaffreyThe Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-6707-8468
Paul M GrandgenettThe Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-6905-1805
Michael A HollingsworthThe Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-5255-8888
Ishani UmmatResolute Bio, Copenhagen, Denmark.ORCID 0009-0003-6371-5812
Maximilian T StraussResolute Bio, Copenhagen, Denmark.ORCID 0000-0003-3320-6833
Andreas MundResolute Bio, Copenhagen, Denmark.ORCID 0000-0002-7843-5341
Anirban MaitraLaura and Isaac Perlmutter Cancer Center, Department of Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0001-7923-9978

Funding

Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
Clinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0M
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elana Fertig · 2022 to 2026
$9.5M
PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education)U24CA274274 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI J. Jack LEE, ANIRBAN MAITRA · 2022 to 2026
$4.9M
Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer ResearchR50CA211462 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Paul M Grandgenett · 2016 to 2026
$1.4M
Hirshberg Foundation for Pancreatic Cancer Research (HFPCR)Lustgarten Foundation (Lustgarten) 25-20-67-BERNNational Cancer Institute (NCI) P01CA117969National Cancer Institute (NCI) P30CA36727National Cancer Institute (NCI) P50CA221707National Cancer Institute (NCI) R50CA211462National Cancer Institute (NCI) U01CA200468National Cancer Institute (NCI) U01CA210240National Cancer Institute (NCI) U01CA284086National Cancer Institute (NCI) U24CA274274National Cancer Institute (NCI) U54CA274329National Cancer Institute (NCI) U54CA274371National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30DK056338NCI NIH HHS R50 CA211462NCI NIH HHS U01 CA200468NCI NIH HHS U01 CA210240NCI NIH HHS U24 CA274274NCI NIH HHS U54 CA274371
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) evolves through precursors, yet the protein programs governing early progression remain poorly defined. We applied Deep Visual Proteomics (DVP)-integrating computational pathology, laser microdissection, and mass spectrometry (MS)-to profile normal ducts, acinar-to-ductal metaplasia (ADM), low-grade (LG) and high-grade (HG) pancreatic intraepithelial neoplasia (PanIN), and invasive carcinoma from organ donors and patients with PDAC. Quantifying 9,181 proteins from ∼100 cells per region, we uncovered a molecular field effect in histologically normal ducts and proteomic divergence of LG-PanINs by cancer context. We identified four stage-associated molecular programs. Stress adaptation and immune engagement emerged early in cancer-associated normal ducts. Metabolic reprogramming initiated in normal ducts and intensified across PanIN progression. Mitochondrial remodeling became prominent in HG-PanINs before invasion. MS detected KRAS hotspot mutant peptides within incidental precursor lesions from cancer-free individuals. These findings demonstrate that molecular reprogramming precedes histologic transformation, creating opportunities for earlier detection of lethal cancer. SIGNIFICANCE: Artificial intelligence (AI)-guided DVP represents the first in-depth assessment of the proteomic landscapes observed during the multistep progression of pancreatic adenocarcinoma, including histologically normal ducts, ADM, and LG- and HG-PanIN lesions. These data represent a unique resource of candidate biomarkers and interception targets against this lethal disease. See related commentary by Yang and Fan, p. 1255.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsProteomicsHumansIntelligent SystemsMetabolic Reprogramming

Identifiers

PMID42013410
PMCPMC13289816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.